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Table 1
Patient characteristics, shown as median (range) unless speciﬁed otherwise.
CB: cordblood
Number of HCTs (n) 196
Number of patients (n) 183
Age (years) 6.55 (0.1-22.7)
Weight (kg) 21 (3.66-96)
BSA (m2) 0.84 (0.14-2.1)
Starting day ATG (days before transplantation) 5.1 (1-19)
Number of samples per patients (n) 12 (4-36)
Diagnosis (%)
Malignancy 48
Immune deﬁciency 22
Bone marrow failure 8
Metabolic disease 13
Benign hematology 8
Stem cell source (%)
Bone marrow 42
Peripheral blood stem cells 11
CB 43
CB plus haplo or 2nd CB 4
Transplant number (1st,2nd,3rd) (n) 183, 12, 1
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Zend framework. TIPS database meets the HIPAA Security
Rule requirements, Title 45 CFR Part 160 and subparts A and
C of Part 164.
Results: TIPS web-based workﬂow tool allows all medical
providers involved in a patient’s transplant broader accessi-
bility to the electronic transplant data during the transplant
process. Medical providers can efﬁciently enter and retrieve
information in real-time. Center administrators are able to
obtain an overview of their Program’s performance, by
generating real-time reports, dashboard views of patient
volumes and distributions, which contribute towards pro-
grammatic quality improvement.
Discussion: TIPS has enabled us to efﬁciently manage pa-
tients throughout the transplant process and improve the
delivery of care and data reporting. Future TIPS enhance-
ments include direct importation of patient demographic
data from Enterprise Electronic Medical Record (EMR), and
connectivity to FormsNet, via AGNIS, for direct transfer of
center transplant data to CIBMTR.PHARMACY
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Figure 2. Observed versus individual predicted concentrations of active Thymoglobulin in all patients split by age. Dots: logtransformed observations, lines: line of
unity (x¼y).
Figure 3. Median (red line) and 95% conﬁdence interval (blue lines) active Thymoglobulin concentrations versus time in patients with a bodyweight of 5, 20, 40 and
60 kg after a cumulative dose of 10 mg/kg given over four days.
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Table 1
AML- Acutemyeloid leukemia; HLH - Hemophagocytic lymphohistiocytosis;
ALL- Acute lymphocytic leukemia; CR e Complete remission; N/A e Not
applicable.
Patient Characteristics
(Numbers)
Diagnosis
AML 8
HLH 1
MDS 3
ALL 2
Disease Status
CR 11
N/A 3
Regimen 9
IV BU/ IV Flu IV BU/ IV Flu + Thymoglobulin
(1.5 mg/kg (T-3 to T-1)
5
Regimen Intensity
AUC 6000 8
AUC 4500 1
AUC 4000 5
Donors
Related 5
Unrelated 9
HLA Match
9/10 2
10/10 12
Median (Range)
CD34 Cells Infused (cells/kg) 7 (2.7-15)
Age at the time of transplant (years) 48.5 (23-61)
Body Surface Area (m2) 1.825 (1.5 e 2.1)
AUC Achieved prior to PK adjustment
(micromole/min)
6000 4482.5 (3652 - 5771)
4000 3221 (2556 - 4579)
Overall AUC Achieved (micromole/min)
6000 5380.5 (4821 - 5978)
4000 4004 (3732 - 4155)
Dose Adjustment
6000 339 (252 - 460)
4000 240 (150 - 273)
Time to Achieve Engraftment (days)
ANC > 500 k/uL 15 (11-20)
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and rejection in hematopoietic cell transplantation (HCT),
children receive anti-thymocyte globulin (ATG), a polyclonal
antibody depleting T-cells, as part of the conditioning
regimen. The therapeutic window is critical as over-exposure
may result in delayed reconstitution of donor T-cells and
increased risk of viral infections. Our objective is to describe
the population pharmacokinetics (PK) of Thymoglobulin as a
ﬁrst step towards an evidence based dosing regimen of
Thymoglobulin for HCT in children.
Methods: PK data were collected for all pediatric HCT’s per-
formed between 2004-2012 in two study centers in the
Netherlands. Serum active Thymoglobulin concentrations
were quantiﬁed by ﬂow cytometry investigating the binding
to a T-cell line. Population modeling and covariate analysis
was performed on active Thymoglobulin concentrations using
NONMEM 7.2. The ﬁnal model was internally validated using
advanced methods such as bootstrap resampling and NPDE.
Results: A total of 196 HCT’s in 183 patients were analyzed
(table 1). A two-compartment model yielded a good
description of the data in all age groups (ﬁgure 1 and 2),
with no evidence for non-linear elimination. The population
value (SE) for clearance (Cl) and volume of distribution (Vd)
of a median individual of 21 kg was 3.4 (0.2) L/day and 8.4
(0.6) L, respectively, with body weight as a signiﬁcant
covariate. The relationship between bodyweight and both Cl
and Vd was best described by a power function with an
exponent of 0.47 (0.08) and 0.62 (0.07), respectively.
Terminal half-life was 4.9 days-1. Figure 3 illustrates that the
currently used dosing regimen of 10 mg/kg leads to higher
exposure in older children compared to younger children.
Conclusion: In the validated population PK model for active
Thymoglobulin in children, clearance and volume of distri-
bution proved dependent on body weight in a nonlinear
manner. Therefore, childrenwith a higher weight are exposed
to higher concentrations compared to lowerweight children if
the currently used dosing regimen of 10 mg/kg bodyweight is
used. Once the optimal therapeutic window is determined in
pharmacodynamic studies, individualized (weight based)
dosing guidelines of Thymoglobulin can be derived leading to
better outcome after pediatric HCT.113
Intravenous(IV) Busulfan (BU) Pharmacokinetics Using
Busulfan and Fludarabine (Flu) Conditioning in
Institutions Where the Capability of Doing
Pharmacokinetics Is Not Present
Zartash Gul 1, Shaily Arora 2, Amber Lawson 2, Heidi L. Weiss 3.
1 Hematology/BMT, University of Kentucky/Markey Cancer
Center, lexington, KY; 2 Pharmacy, University of Kentucky,
Lexington, KY; 3 Professor department of Biostatistics, 800 Rose
street, Markey Cancer Center, Lexington, KY
Background: IV BU overcomes the wide variation in
achieving steady state drug concentration associated with its
oral administration. Many institutions are limited in using IV
BU because of an inability to perform PK analysis at an
institutional level. At Markey Cancer Center we utilized a
unique strategy for administering IV BU in order to facilitate
PK analysis at an off-site laboratory.
Methods: This is a retrospective, chart review of 14 patients
admitted for allogeneic stem cell transplant between
November 2012 - September 2013 who received a condi-
tioning regimen of IV BU and IV ﬂu. Flu (30 mg/m2) was
administered daily on days T-7 through T-3. BU dosing
(desired area under the curve (AUC)) was determined based
on patient age and performance status based per physiciandiscretion. BU PK calculations were performed by the Seattle
Cancer Care Alliance Pharmacokinetics Laboratory, Seattle,
WA. Growth factors were not used. Patients received a once-
daily BU dose (based on BSA) on days T-7 and T-5. On day T-7,
BU levels were collected at the end of the infusion, 15 mi-
nutes after completion of the infusion, and at 4, 5 ,6, and 8
hours after the start of infusion. Patients did not receive BU
on day T-6 in order to facilitate the ability to use PK analysis
to adjust the last two BU doses on T-4 and T-3.
Results: Patient characteristics are described in Table 1. The
median BU AUC achieved for the myeloabalative group was
5380.5 (4821 - 5978) uMol/min and reduced intensity
group was 4004 (3732 - 4155) uMol/min. Acute GVHD was
observed in six and chronic in two patients. Two patients
also developed cytomegalovirus related disease. One patient
relapsed at day 88 with 4% blasts on bone marrow biopsy.
After a median follow up 176 days all patients are alive.
Conclusions: Our results demonstrate that PK-guided IV BU-
based conditioning regimens could be used in institutions
where the ability to perform institutional PK is not present.
More patients and longer follow-up time would be required
to conclusively determine the effectiveness of this approach.114
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